Radioactive therapy targets hard-to-treat leukemia in early trial

NCT ID NCT06356922

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Apr 25, 2026 · Last updated May 14, 2026 · Updated 3 times

Summary

This study tests a new radioactive drug (177Lu-PentixaTher) for people with acute leukemia that has come back or not responded to other treatments. The drug seeks out and delivers radiation to leukemia cells that have a specific marker (CXCR4). The main goals are to find the safest dose and see if it can shrink the cancer. About 21 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU d'Angers
RECRUITING

Angers, Maine et Loire, 49100, France

Contact Email: •••••@•••••
CHU de Bordeaux
RECRUITING

Bordeaux, Gironde, 33604, France

Contact

Contact
CHU de Clermont-Ferrand
RECRUITING

Clermont-Ferrand, Puy de Dôme, 63000, France

Contact Email: •••••@•••••
CHU de Nantes
RECRUITING

Nantes, Loire-Atlantique, 44000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE LEUKEMIA